Entero Therapeutics Ownership 2024 | Who Owns Entero Therapeutics Now?

Overview Forecast RevenueFinancials Chart

Institutional Ownership

1.11%

Insider Ownership

5.66%

Retail Ownership

93.23%

Institutional Holders

15.00

Entero Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	87.57%	0.00%	89,856	89,856	100.00%	240,814,000	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	12.92%	0.00%	13,258	13,258	100.00%	35,000	Mar 31, 2023
STATE STREET CORP	11.50%	-	11,797	11,797	100.00%	31,616,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	4.36%	0.00%	4,477	4,477	100.00%	12,000	Mar 31, 2023
UBS GROUP AG	4.00%	-	4,106	4,106	100.00%	11,004,000	Mar 31, 2023
BLACKROCK INC.	0.39%	-	397	397	100.00%	1,064,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.03%	-	33	33	100.00%	89,000	Mar 31, 2023
US BANCORP \DE\	0.02%	-	24	24	100.00%	64,000	Mar 31, 2023
KATHLEEN S. WRIGHT ASSOCIATES INC.	0.02%	-	22	22	100.00%	59,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	1	1	100.00%	3,000	Mar 31, 2023
FIRST MANHATTAN CO. LLC.	0.00%	-	1	1	100.00%	2,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-33	-100.00%	-	Mar 31, 2023
HARTFORD FINANCIAL MANAGEMENT INC.	-	-	-	-1	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-2,183	-100.00%	-	Mar 31, 2023
US BANCORP \DE\	-	-	-	-25	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-2,038	-100.00%	-	Mar 31, 2023
STATE STREET CORP	-	-	-	-11,799	-100.00%	-	Mar 31, 2023
MONEY CONCEPTS CAPITAL CORP	-	-	-	-5	-100.00%	-	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-7,178	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-4	-100.00%	-	Mar 31, 2023

Entero Therapeutics's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 87.57% of the company's total share outstanding, currently valued at $240.81M. The top 10 institutional shareholders own together 120.82% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	87.57%	0.00%	89,856	89,856	100.00%	240,814,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	4.36%	0.00%	4,477	4,477	100.00%	12,000	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	12.92%	0.00%	13,258	13,258	100.00%	35,000	Mar 31, 2023
KATHLEEN S. WRIGHT ASSOCIATES INC.	0.02%	-	22	22	100.00%	59,000	Mar 31, 2023
UBS GROUP AG	4.00%	-	4,106	4,106	100.00%	11,004,000	Mar 31, 2023
STATE STREET CORP	11.50%	-	11,797	11,797	100.00%	31,616,000	Mar 31, 2023
US BANCORP \DE\	0.02%	-	24	24	100.00%	64,000	Mar 31, 2023
BLACKROCK INC.	0.39%	-	397	397	100.00%	1,064,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.03%	-	33	33	100.00%	89,000	Mar 31, 2023
FIRST MANHATTAN CO. LLC.	0.00%	-	1	1	100.00%	2,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	1	1	100.00%	3,000	Mar 31, 2023
US BANCORP \DE\	-	-	-	-25	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-2,183	-100.00%	-	Mar 31, 2023
STATE STREET CORP	-	-	-	-11,799	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-2,038	-100.00%	-	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-7,178	-100.00%	-	Mar 31, 2023
MONEY CONCEPTS CAPITAL CORP	-	-	-	-5	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-971	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-1,530	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-4	-100.00%	-	Mar 31, 2023

The largest Entero Therapeutics shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 89.86K shares of Entero Therapeutics (FWBI), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	87.57%	0.00%	89,856	89,856	100.00%	240,814,000	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	12.92%	0.00%	13,258	13,258	100.00%	35,000	Mar 31, 2023
STATE STREET CORP	11.50%	-	11,797	11,797	100.00%	31,616,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	4.36%	0.00%	4,477	4,477	100.00%	12,000	Mar 31, 2023
UBS GROUP AG	4.00%	-	4,106	4,106	100.00%	11,004,000	Mar 31, 2023
BLACKROCK INC.	0.39%	-	397	397	100.00%	1,064,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.03%	-	33	33	100.00%	89,000	Mar 31, 2023
US BANCORP \DE\	0.02%	-	24	24	100.00%	64,000	Mar 31, 2023
KATHLEEN S. WRIGHT ASSOCIATES INC.	0.02%	-	22	22	100.00%	59,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	1	1	100.00%	3,000	Mar 31, 2023
FIRST MANHATTAN CO. LLC.	0.00%	-	1	1	100.00%	2,000	Mar 31, 2023
HARTFORD FINANCIAL MANAGEMENT INC.	-	-	-	-1	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-2	-100.00%	-	Mar 31, 2023
FIRST MANHATTAN CO. LLC.	-	-	-	-2	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-4	-100.00%	-	Mar 31, 2023
MONEY CONCEPTS CAPITAL CORP	-	-	-	-5	-100.00%	-	Mar 31, 2023
US BANCORP \DE\	-	-	-	-25	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-33	-100.00%	-	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-286	-100.00%	-	Mar 31, 2023
BLACKROCK INC.	-	-	-	-399	-100.00%	-	Mar 31, 2023

As of Mar 31 2023, Entero Therapeutics's largest institutional buyer is ARMISTICE CAPITAL, LLC. The company purchased 89.86K stocks of FWBI, valued at $240.81M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	-	-	-	-41,996	-100.00%	-	Mar 31, 2023
STATE STREET CORP	-	-	-	-11,799	-100.00%	-	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-7,178	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-2,183	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-2,038	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-1,530	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-971	-100.00%	-	Mar 31, 2023
BLACKROCK INC.	-	-	-	-399	-100.00%	-	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-286	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-33	-100.00%	-	Mar 31, 2023
US BANCORP \DE\	-	-	-	-25	-100.00%	-	Mar 31, 2023
MONEY CONCEPTS CAPITAL CORP	-	-	-	-5	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-4	-100.00%	-	Mar 31, 2023
FIRST MANHATTAN CO. LLC.	-	-	-	-2	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-2	-100.00%	-	Mar 31, 2023
HARTFORD FINANCIAL MANAGEMENT INC.	-	-	-	-1	-100.00%	-	Mar 31, 2023
FIRST MANHATTAN CO. LLC.	0.00%	-	1	1	100.00%	2,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	1	1	100.00%	3,000	Mar 31, 2023
KATHLEEN S. WRIGHT ASSOCIATES INC.	0.02%	-	22	22	100.00%	59,000	Mar 31, 2023
US BANCORP \DE\	0.02%	-	24	24	100.00%	64,000	Mar 31, 2023

As of Mar 31 2023, Entero Therapeutics's biggest institutional seller is ARMISTICE CAPITAL, LLC. The company sold -42.00K shares of FWBI, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	87.57%	0.00%	89,856	89,856	100.00%	240,814,000	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	12.92%	0.00%	13,258	13,258	100.00%	35,000	Mar 31, 2023
STATE STREET CORP	11.50%	-	11,797	11,797	100.00%	31,616,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	4.36%	0.00%	4,477	4,477	100.00%	12,000	Mar 31, 2023
UBS GROUP AG	4.00%	-	4,106	4,106	100.00%	11,004,000	Mar 31, 2023
BLACKROCK INC.	0.39%	-	397	397	100.00%	1,064,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.03%	-	33	33	100.00%	89,000	Mar 31, 2023
US BANCORP \DE\	0.02%	-	24	24	100.00%	64,000	Mar 31, 2023
KATHLEEN S. WRIGHT ASSOCIATES INC.	0.02%	-	22	22	100.00%	59,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	1	1	100.00%	3,000	Mar 31, 2023
FIRST MANHATTAN CO. LLC.	0.00%	-	1	1	100.00%	2,000	Mar 31, 2023

Entero Therapeutics's largest new institutional shareholder by number of shares is ARMISTICE CAPITAL, LLC, purchased 89.86K shares, valued at $240.81M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ARMISTICE CAPITAL, LLC	-	-	-	-41,996	-100.00%	-	Mar 31, 2023
STATE STREET CORP	-	-	-	-11,799	-100.00%	-	Mar 31, 2023
ACADIAN ASSET MANAGEMENT LLC	-	-	-	-7,178	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-2,183	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-2,038	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-1,530	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-971	-100.00%	-	Mar 31, 2023
BLACKROCK INC.	-	-	-	-399	-100.00%	-	Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.	-	-	-	-286	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-33	-100.00%	-	Mar 31, 2023
US BANCORP \DE\	-	-	-	-25	-100.00%	-	Mar 31, 2023
MONEY CONCEPTS CAPITAL CORP	-	-	-	-5	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-4	-100.00%	-	Mar 31, 2023
FIRST MANHATTAN CO. LLC.	-	-	-	-2	-100.00%	-	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	-	-2	-100.00%	-	Mar 31, 2023
HARTFORD FINANCIAL MANAGEMENT INC.	-	-	-	-1	-100.00%	-	Mar 31, 2023

Entero Therapeutics's largest sold out institutional shareholder by shares sold is ARMISTICE CAPITAL, LLC, sold -42.00K shares, valued at -, as of undefined.

Entero Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY CONCORD STREET TRUST	0.00%	87,161	-	-	Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	6,493	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	42,325	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	16,478	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	2,776	2,776	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	4,535	2,889	175.52%	Mar 31, 2024
USAA MUTUAL FUNDS TRUST	0.00%	2,322	-	-	Jan 31, 2024
iSHARES TRUST	0.00%	83,119	-	-	Mar 31, 2024
VANGUARD INDEX FUNDS	0.00%	400	-	-	Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	1,623	-	-	Mar 31, 2024

Entero Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 87.16K shares, compromising 0.00% of its total assets.

Entero Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Jun, 22	15	-
31 Mar, 22	15	-6.25%
31 Dec, 21	16	14.29%
30 Sep, 21	14	-

As of 30 Jun 22, 15 institutions are holding Entero Therapeutics's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Jun, 22	533,210	-2.51%
31 Mar, 22	546,962	-23.58%
31 Dec, 21	715,710	33.20%
30 Sep, 21	537,339	-

Entero Therapeutics (FWBI) has 533.21K shares outstanding as of 30 Jun 22, down -2.51% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Jun, 22	1.11%	85.63%
31 Mar, 22	1.14%	51.30%
31 Dec, 21	1.49%	119.09%
30 Sep, 21	1.12%	-

As of 30 Jun 22, Entero Therapeutics is held by 1.11% institutional shareholders, representing a 85.63% growth compared to 31 Mar 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Jun, 22	7	-
31 Mar, 22	7	-12.50%
31 Dec, 21	8	-42.86%
30 Sep, 21	14	-

7 institutional shareholders have increased their position in FWBI stock as of 30 Jun 22 compared to 7 in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Jun, 22	2	-
31 Mar, 22	2	-50.00%
31 Dec, 21	4	-
30 Sep, 21	-	-

2 institutional shareholders have reduced their position in FWBI stock as of 30 Jun 22 compared to 2 in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Jun, 22	15	-	533,210	-2.51%	1.11%	85.63%	7	-	2	-
31 Mar, 22	15	-6.25%	546,962	-23.58%	1.14%	51.30%	7	-12.50%	2	-50.00%
31 Dec, 21	16	14.29%	715,710	33.20%	1.49%	119.09%	8	-42.86%	4	-
30 Sep, 21	14	-	537,339	-	1.12%	-	14	-	-	-

Entero Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Apr 03, 2024	SAPIRSTEIN JAMES	director, officer	Chairman and CEO	S-Sale	Sell	174	$4.23	$735.92	37,105
Apr 03, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	75	$4.23	$317.20	19,111
Mar 19, 2024	SAPIRSTEIN JAMES	director, officer	Chairman and CEO	S-Sale	Sell	1,887	$4.96	$9.36K	37,279
Mar 19, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	1,120	$4.96	$5.56K	19,186
Jan 17, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	98	$4.20	$411.60	20,306
Jan 17, 2024	SAPIRSTEIN JAMES	director, officer	Chairman, President and CEO	S-Sale	Sell	166	$4.20	$697.20	39,166

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Apr 03, 2024	SAPIRSTEIN JAMES	director, officer	Chairman and CEO	S-Sale	Sell	174	$4.23	$735.92	37,105
Apr 03, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	75	$4.23	$317.20	19,111
Mar 19, 2024	SAPIRSTEIN JAMES	director, officer	Chairman and CEO	S-Sale	Sell	1,887	$4.96	$9.36K	37,279
Mar 19, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	1,120	$4.96	$5.56K	19,186
Jan 17, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	98	$4.20	$411.60	20,306
Jan 17, 2024	SAPIRSTEIN JAMES	director, officer	Chairman, President and CEO	S-Sale	Sell	166	$4.20	$697.20	39,166

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Apr 03, 2024	SAPIRSTEIN JAMES	director, officer	Chairman and CEO	S-Sale	Sell	174	$4.23	$735.92	37,105
Apr 03, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	75	$4.23	$317.20	19,111
Mar 19, 2024	SAPIRSTEIN JAMES	director, officer	Chairman and CEO	S-Sale	Sell	1,887	$4.96	$9.36K	37,279
Mar 19, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	1,120	$4.96	$5.56K	19,186
Mar 15, 2024	Syage Jack	director, officer	President & COO	A-Award	Buy	15,400	-	$1.54	15,400
Mar 15, 2024	Syage Jack	director, officer	President & COO	A-Award	Buy	4,920	-	-	4,920
Mar 15, 2024	KHOSLA CHAITAN PHD	director	-	A-Award	Buy	52,980	$0.81	$42.91K	52,980
Mar 15, 2024	KHOSLA CHAITAN PHD	director	-	A-Award	Buy	440	-	$0.04	440
Mar 15, 2024	KHOSLA CHAITAN PHD	director	-	A-Award	Buy	140	-	-	140
Mar 15, 2024	KHOSLA CHAITAN PHD	director			Buy	-	-	-	-
Mar 15, 2024	Syage Jack	director, officer	President & COO		Buy	-	-	-	-
Jan 17, 2024	Romano Sarah	officer	Chief Financial Officer	S-Sale	Sell	98	$4.20	$411.60	20,306
Jan 17, 2024	SAPIRSTEIN JAMES	director, officer	Chairman, President and CEO	S-Sale	Sell	166	$4.20	$697.20	39,166
Jan 04, 2024	CASAMENTO CHARLES J	director	-	A-Award	Buy	19,633	-	-	19,937
Jan 04, 2024	Riddell Alastair	director	-	A-Award	Buy	19,633	-	-	20,240
Jan 04, 2024	Coelho Mary Theresa	director	-	A-Award	Buy	19,633	-	-	20,237
Jan 04, 2024	BORKOWSKI EDWARD	director	-	A-Award	Buy	19,633	-	-	20,248
Jan 03, 2024	SAPIRSTEIN JAMES	director, officer	Chairman, President and CEO	A-Award	Buy	20,000	-	-	39,332
Jan 03, 2024	SAPIRSTEIN JAMES	director, officer	Chairman, President and CEO	A-Award	Buy	17,660	-	-	19,332
Jan 03, 2024	Romano Sarah	officer	Chief Financial Officer	A-Award	Buy	7,000	-	-	20,404

The last insider sell of Entero Therapeutics's stock was made by SAPIRSTEIN JAMES on Apr 03 2024, selling 174 shares at $4.23 per share (valued at $735.92).

Entero Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	-	2	-
Q1 2024	11	4	275.00%
Q4 2023	2	2	100.00%
Q3 2023	-	4	-
Q2 2023	-	2	-
Q1 2023	7	-	-
Q2 2022	-	1	-
Q1 2022	10	-	-
Q3 2021	2	-	-
Q2 2021	3	2	150.00%
Q1 2021	5	-	-
Q3 2020	9	2	450.00%
Q2 2020	7	1	700.00%
Q1 2020	16	4	400.00%
Q4 2019	8	-	-
Q3 2019	4	-	-
Q2 2019	13	-	-
Q1 2019	10	4	250.00%
Q4 2018	11	-	-
Q3 2018	9	-	-

0 total buy trades, and 2 total sell trades (buy/sell ratio of 0.00%) were made by Entero Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	-	2	-
Q1 2024	-	4	-
Q4 2023	-	2	-
Q3 2023	-	4	-
Q2 2023	-	2	-
Q1 2023	-	-	-
Q2 2022	-	-	-
Q1 2022	-	-	-
Q3 2021	-	-	-
Q2 2021	-	-	-
Q1 2021	-	-	-
Q3 2020	-	-	-
Q2 2020	-	-	-
Q1 2020	-	-	-
Q4 2019	-	-	-
Q3 2019	-	-	-
Q2 2019	-	-	-
Q1 2019	6	-	-
Q4 2018	7	-	-
Q3 2018	-	-	-

As of Q2 2024, Insider owners conducted 0 open market buy trades and 2 open market sell trades of Entero Therapeutics's stocks.

Entero Therapeutics Peer Ownership

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
XFOR	X4 Pharmaceuticals, Inc.
CFRX	ContraFect Corporation
VIRI	Virios Therapeutics, Inc.
ICU	SeaStar Medical Holding Corporation
BWV	Onconetix, Inc.
PXMD	PaxMedica, Inc. Common Stock
PHIO	Phio Pharmaceuticals Corp.
REVB	Revelation Biosciences, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
HILS	Tharimmune, Inc.
SGTX	Sigilon Therapeutics, Inc.
DRMA	Dermata Therapeutics, Inc.
EFTR	eFFECTOR Therapeutics, Inc.
IMMX	Immix Biopharma, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.
ZURA	Zura Bio Limited
CDIO	Cardio Diagnostics Holdings, Inc.

FWBI Ownership FAQ

Who Owns Entero Therapeutics?

Entero Therapeutics is owned by institutional shareholders (1.11%), insiders (5.66%), and public (93.23%). The largest institutional shareholder of Entero Therapeutics is ARMISTICE CAPITAL, LLC (87.57% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).

Who are the major institutional shareholders of Entero Therapeutics?

Entero Therapeutics's major institutional shareholders are ARMISTICE CAPITAL, LLC, ACADIAN ASSET MANAGEMENT LLC, STATE STREET CORP, TOWER RESEARCH CAPITAL LLC (TRC), and UBS GROUP AG. The top five shareholders own together 120.36% of the company's share outstanding.

How many Entero Therapeutics shareholders are there?

As of Jun 2022, there are 15 institutional shareholders of Entero Therapeutics.

What percentage of Entero Therapeutics is owned by ARMISTICE CAPITAL, LLC?

ARMISTICE CAPITAL, LLC owns 89.86K shares of Entero Therapeutics, representing 87.57% of the company's total shares outstanding, valued at $240.81M (as of Mar 2023).

What percentage of Entero Therapeutics is owned by ACADIAN ASSET MANAGEMENT LLC?

As of Mar 2023, ACADIAN ASSET MANAGEMENT LLC holds 13.26K shares of Entero Therapeutics (FWBI), compromising 12.92% of the company, valued at $35K.

What percentage of Entero Therapeutics is owned by STATE STREET CORP?

STATE STREET CORP is the third largest holder of Entero Therapeutics. The company owns 11.8K of the company's shares outstanding (worth $31.62M).